Celldex Therapeutics (NASDAQ:CLDX) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report issued on Tuesday morning, MarketBeat reports. The firm issued a buy rating and a $58.00 target price on the biopharmaceutical company’s stock.

Other equities analysts also recently issued reports about the company. Guggenheim lifted their target price on Celldex Therapeutics from $72.00 to $90.00 and gave the company a buy rating in a research report on Tuesday, February 27th. Cantor Fitzgerald reiterated an overweight rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Friday, March 22nd. HC Wainwright reiterated a buy rating and set a $80.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 3rd. Finally, Wolfe Research began coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They set an outperform rating and a $51.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Celldex Therapeutics presently has an average rating of Moderate Buy and an average price target of $62.17.

Celldex Therapeutics Price Performance

CLDX stock opened at $34.66 on Tuesday. The company has a market cap of $2.28 billion, a P/E ratio of -12.16 and a beta of 1.48. Celldex Therapeutics has a 1 year low of $22.11 and a 1 year high of $53.18. The stock’s fifty day moving average price is $37.54 and its 200-day moving average price is $39.06.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $1.30 million. Celldex Therapeutics had a negative return on equity of 29.55% and a negative net margin of 2,385.57%. As a group, analysts expect that Celldex Therapeutics will post -2.32 earnings per share for the current year.

Insider Activity

In other news, CFO Samuel Bates Martin sold 35,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the transaction, the chief financial officer now directly owns 25,128 shares in the company, valued at $855,608.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Margo Heath-Chiozzi sold 38,719 shares of Celldex Therapeutics stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.07, for a total value of $1,319,156.33. Following the sale, the senior vice president now directly owns 7,094 shares of the company’s stock, valued at $241,692.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Samuel Bates Martin sold 35,000 shares of Celldex Therapeutics stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the sale, the chief financial officer now directly owns 25,128 shares in the company, valued at $855,608.40. The disclosure for this sale can be found here. Insiders have sold 266,332 shares of company stock worth $9,155,821 over the last ninety days. Corporate insiders own 3.80% of the company’s stock.

Institutional Investors Weigh In On Celldex Therapeutics

Several large investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in shares of Celldex Therapeutics by 19.2% in the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock worth $256,860,000 after purchasing an additional 1,044,728 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock worth $153,215,000 after purchasing an additional 604,251 shares during the last quarter. Eventide Asset Management LLC increased its holdings in shares of Celldex Therapeutics by 126.9% in the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock worth $143,966,000 after purchasing an additional 2,030,013 shares during the last quarter. Kynam Capital Management LP increased its stake in Celldex Therapeutics by 23.1% during the third quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock worth $88,064,000 after acquiring an additional 600,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its stake in Celldex Therapeutics by 631.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after acquiring an additional 2,664,915 shares during the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.